262368-64-9

Basic information

• Product Name: 4-(4-METHYL-PIPERIDIN-1-YLMETHYL)-PHENYLAMINE
• Synonyms: 4-(4-METHYL-PIPERIDIN-1-YLMETHYL)-PHENYLAMINE;AKOS BC-2587;TIMTEC-BB SBB011089;4-[(4-Methyl-1-piperidinyl)methyl]aniline
• CAS NO: 262368-64-9
• Molecular Formula: C13H20N2
• Molecular Weight: 204.31
• Mol File: 262368-64-9.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-METHYL-PIPERIDIN-1-YLMETHYL)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-METHYL-PIPERIDIN-1-YLMETHYL)-PHENYLAMINE(262368-64-9)
• EPA Substance Registry System: 4-(4-METHYL-PIPERIDIN-1-YLMETHYL)-PHENYLAMINE(262368-64-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 262368-64-9(Hazardous Substances Data)

Usage

General Description

4-(4-methyl-piperidin-1-ylmethyl)-phenylamine is a chemical compound with the molecular formula C16H24N2. It is a substituted phenylamine with a piperidine group and a methyl group attached to the fourth carbon of the piperidine ring. 4-(4-METHYL-PIPERIDIN-1-YLMETHYL)-PHENYLAMINE is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and chemicals. It is also used as a reagent in organic synthesis and in the production of fine chemicals. The compound has potential applications in medicinal chemistry and drug discovery due to its structural features and functional groups. Additionally, it has shown promise in the treatment of various diseases and disorders. Due to its potential biological activities, this compound is of interest to researchers in the fields of pharmacology, medicinal chemistry, and chemical biology.

Upstream product

• 626-58-4 4-methylpiperidin 
• 100-11-8 1-bromomethyl-4-nitro-benzene 

Relevant articles and documents

Semicarbazone derivative serving as caspase-3 activator and application thereof

The invention provides semicarbazone derivative serving as a caspase-3 activator and application thereof. A structural general formula of the semicarbazone derivative or pharmaceutically acceptable salts of the semicarbazone derivative is shown as a formula I shown in the description. The semicarbazone derivative disclosed by the invention can be applied to preparing of medicine for treating or preventing cancer diseases and other hyperplastic diseases; thus, treating or preventing the cancer diseases and other hyperplastic diseases, and the semicarbazone derivative has an excellent application prospect in the aspect of developing antineoplastic medicine.

Design, synthesis and antiproliferative activity of novel benzothiazole derivatives conjugated with semicarbazone scaffold

Two series of novel benzothiazole derivatives conjugated with semicarbazone scaffold were designed and synthesized through a structure-based molecular hybridization strategy. All the target compounds were evaluated for their cytotoxicity in vitro against three cancer cell lines (HT-29, MKN-45 and H460) by standard MTT assay. The pharmacological results indicated that seven compounds (17h-n) exhibited comparable or even better antiproliferative activity in comparison with reference drugs Sorafenib and PAC-1. Particularly, compound 17i displayed remarkable cytotoxicity against tested three cancer cell lines with IC50 values of 0.84, 0.06 and 0.52 μM, which were 4.3-, 36.6-, 4.2-folds more potent than Sorafenib and 1.2-, 13.7-, 6.9-times more active than PAC-1, respectively.

Synthesis and biological evaluation of benzothiazole derivatives bearing the ortho-hydroxy-N-acylhydrazone moiety as potent antitumor agents

A novel series of benzothiazole derivatives bearing the ortho-hydroxy-N-acylhydrazone moiety were designed, synthesized, and evaluated for their procaspase-3 kinase activation activities and antiproliferative activities against five cancer cell lines (NCI-H226, SK-N-SH, HT29, MKN-45, and MDA-MB-231). Most target compounds showed moderate to excellent cytotoxic activity against all five tested cancer lines. The most promising compound 18e (procaspase-3 EC50- 0.31μM) with IC50 values ranging from 0.24 to 0.92 μM against all tested cell lines was 4.24-12.2 times more active than PAC-1 (procaspase-3 EC50 - 0.41 μM). Structure-activity relationship studies indicated that the phenyl group on the 2-hydroxyphenyl ring (moiety A) was critical for pharmacological activity in vitro. In addition, introduction of a benzyloxyl group on moiety A and a mono-electron-withdrawing group at the 4-position of the benzyloxyl group were more favorable for antitumor activity. Moreover, reduction of the electron density in the phenyl ring of the benzyloxy group led to a dramatic decrease in the procaspase-3 kinase activation activity. -